| A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis JN Feder, A Gnirke, W Thomas, Z Tsuchihashi, DA Ruddy, A Basava, ... Nature genetics 13 (4), 399-408, 1996 | 4662 | 1996 |
| High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response H Gao, JM Korn, S Ferretti, JE Monahan, Y Wang, M Singh, C Zhang, ... Nature medicine 21 (11), 1318-1325, 2015 | 1313 | 2015 |
| aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation R Francis, G McGrath, J Zhang, DA Ruddy, M Sym, J Apfeld, M Nicoll, ... Developmental cell 3 (1), 85-97, 2002 | 1179 | 2002 |
| Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ... Nature medicine 22 (3), 262-269, 2016 | 909 | 2016 |
| HFE gene knockout produces mouse model of hereditary hemochromatosis XY Zhou, S Tomatsu, RE Fleming, S Parkkila, A Waheed, J Jiang, Y Fei, ... Proceedings of the National Academy of Sciences 95 (5), 2492-2497, 1998 | 619 | 1998 |
| An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) M Korpal, JM Korn, X Gao, DP Rakiec, DA Ruddy, S Doshi, J Yuan, ... Cancer discovery 3 (9), 1030-1043, 2013 | 600 | 2013 |
| Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening ER McDonald, A De Weck, MR Schlabach, E Billy, KJ Mavrakis, ... Cell 170 (3), 577-592. e10, 2017 | 597 | 2017 |
| Studying clonal dynamics in response to cancer therapy using high-complexity barcoding HC Bhang, DA Ruddy, V Krishnamurthy Radhakrishna, JX Caushi, ... Nature medicine 21 (5), 440-448, 2015 | 519 | 2015 |
| Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 KJ Mavrakis, ER McDonald III, MR Schlabach, E Billy, GR Hoffman, ... Science 351 (6278), 1208-1213, 2016 | 426 | 2016 |
| CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions DM Munoz, PJ Cassiani, L Li, E Billy, JM Korn, MD Jones, J Golji, ... Cancer discovery 6 (8), 900-913, 2016 | 377 | 2016 |
| Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss H Liu, J Golji, LK Brodeur, FS Chung, JT Chen, RS deBeaumont, ... Nature medicine 25 (1), 95-102, 2019 | 251 | 2019 |
| SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors L Dardaei, HQ Wang, M Singh, P Fordjour, KX Shaw, S Yoda, G Kerr, ... Nature medicine 24 (4), 512-517, 2018 | 185 | 2018 |
| Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer S Raoof, IJ Mulford, H Frisco-Cabanos, V Nangia, D Timonina, E Labrot, ... Oncogene 38 (37), 6399-6413, 2019 | 178 | 2019 |
| KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer EB Krall, B Wang, DM Munoz, N Ilic, S Raghavan, MJ Niederst, K Yu, ... Elife 6, e18970, 2017 | 150 | 2017 |
| Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors V Gibaja, F Shen, J Harari, J Korn, D Ruddy, V Saenz-Vash, H Zhai, ... Oncogene 35 (5), 558-566, 2016 | 147 | 2016 |
| A chemical genetics approach for the functional assessment of novel cancer genes Q Zhou, A Derti, D Ruddy, D Rakiec, I Kao, M Lira, V Gibaja, HM Chan, ... Cancer research 75 (10), 1949-1958, 2015 | 130 | 2015 |
| A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients R Tiedt, E Degenkolbe, P Furet, BA Appleton, S Wagner, J Schoepfer, ... Cancer research 71 (15), 5255-5264, 2011 | 126 | 2011 |
| Single nucleotide polymorphism markers for genetic mapping in Drosophila melanogaster RA Hoskins, AC Phan, M Naeemuddin, FA Mapa, DA Ruddy, JJ Ryan, ... Genome research 11 (6), 1100-1113, 2001 | 125 | 2001 |
| TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts AL Grauel, B Nguyen, D Ruddy, T Laszewski, S Schwartz, J Chang, ... Nature communications 11 (1), 6315, 2020 | 120 | 2020 |
| Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus H Huynh, HX Hao, SL Chan, D Chen, R Ong, KC Soo, P Pochanard, ... Molecular cancer therapeutics 14 (5), 1224-1235, 2015 | 116 | 2015 |
